id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC5302928 | core_pubmed_pmc | [ 64 Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma | [ 64 Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma Abstract Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We synthesized and performed in vit... |
PMC3984021 | core_pubmed_pmc | Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial | Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial Abstract Abstract Background Preliminary research shows ginger may be an effective adjuvant treatment for chemotherapy-induced nausea and vomiting but significant limitations need to be addressed before re... |
PMC11769416 | core_pubmed_pmc | Whole-Body Physiologically Based Pharmacokinetic Modeling of GalNAc-Conjugated siRNAs | Whole-Body Physiologically Based Pharmacokinetic Modeling of GalNAc-Conjugated siRNAs Abstract Abstract Background/Objectives : N-acetyl-galactosamine small interfering RNAs (GalNAc-siRNA) are an emerging class of drugs due to their durable knockdown of disease-related proteins. Direct conjugation of GalNAc onto the si... |
PMC9244942 | core_pubmed_pmc | A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT) | A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT) Abstract Abstract Purpose: Regorafenib monotherapy, a multikinase inhibitor of angiogenesis, tumor microenvironment, and tumorigenesis, showed promising results in gastric cancer. We aimed to... |
PMC3873531 | core_pubmed_pmc | Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling | Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling Abstract Abstract Hypoxia contributes to resistance of tumors to some cytotoxic drugs and to radiotherapy, but can in principle be exploited with hypoxia-activated prodrugs (HAP). HAP in clinical development fall into two broa... |
PMC5446118 | core_pubmed_pmc | Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida | Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida Abstract Abstract Pharmacokinetic-pharmacodynamic (PK/PD) integration and modelling were used to predict dosage schedules for florfenicol for two pig pneumon... |
PMC6282586 | core_pubmed_pmc | Pharmacokinetics, Excretion, and Mass Balance of [ 14 C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men | Pharmacokinetics, Excretion, and Mass Balance of [ 14 C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men Abstract Abstract Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive p... |
PMC9395450 | core_pubmed_pmc | Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors | Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors Abstract Abstract Summary Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated c... |
PMC6611566 | core_pubmed_pmc | Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology | Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology Conclusion Conclusions Modern drug development tools using quantitative and translational pharmacology and microbiology are proving to be invaluable when applied to TB drug an... |
PMC10349186 | core_pubmed_pmc | Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients | Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients Abstract Abstract Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, the population pharmacokinetic (PK) characteri... |
PMC11626803 | core_pubmed_pmc | Combined therapeutic option for NDM-producing Serratia Marcescens – an in vitro study from clinical samples | Combined therapeutic option for NDM-producing Serratia Marcescens – an in vitro study from clinical samples Abstract Abstract Background Treating NDM-producing bacteria poses a significant challenge, especially for those bacteria inherently resistant to polymyxin, such as Serratia marcescens , necessitating combined th... |
PMC11162967 | core_pubmed_pmc | Combined Hydroxyethyl Starch Luteolin Nanocrystals for Effective Anti-Hyperuricemia Effect in Mice Model | Combined Hydroxyethyl Starch Luteolin Nanocrystals for Effective Anti-Hyperuricemia Effect in Mice Model Abstract Abstract Introduction Although flavonoid compounds exhibit various pharmacological activities, their clinical applications are restricted by low oral bioavailability owing to their poor solubility. Nanocrys... |
PMC5306366 | core_pubmed_pmc | Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting | Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting Abstract Cancer stem cells (CSCs) have been reported to play critical roles in tumor initiation, propagation, and regeneration of cancer. Nano-size vehicles are employed to deliver drugs to target the CSCs for cancer therapy. Polymeric nanoparticles hav... |
PMC9490176 | core_pubmed_pmc | Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo | Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo Abstract Abstract It has been reported that drug-drug interactions (DDIs) can affect the pharmacokinetics and pharmacodynamics of various oral drugs. To better understand the effects of azole an... |
PMC11864979 | core_pubmed_pmc | First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer | First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer Abstract Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α ( Map... |
PMC11652969 | core_pubmed_pmc | Association of mixed polycyclic aromatic hydrocarbons exposure with cardiovascular disease and the mediating role of inflammatory indices in US adults | Association of mixed polycyclic aromatic hydrocarbons exposure with cardiovascular disease and the mediating role of inflammatory indices in US adults Abstract Abstract Background Cardiovascular disease (CVD) is the leading cause of death worldwide. Few studies have investigated the effects of mixed polycyclic aromatic... |
PMC10499409 | core_pubmed_pmc | Abemaciclib does not increase the corrected QT interval in healthy participants | Abemaciclib does not increase the corrected QT interval in healthy participants Abstract Abstract Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use an exposure–response app... |
PMC6709487 | core_pubmed_pmc | Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis | Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis Abstract Cryptococcus spp., important fungal pathogens, are the leading cause of fungus-related mortality in human immunodeficiency virus-infected patients, and new therapeutic options are desperately needed. Isavuconazonium sulfate... |
PMC10272745 | core_pubmed_pmc | A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides | A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides Abstract Abstract Intrathecal administration is an important mode for delivering biological agents targeting central nervous system (CNS) diseases. However, current clinical practices lack a sound theorical basis for a quan... |
PMC8697921 | core_pubmed_pmc | New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach | New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach Abstract Abstract Simple Summary The prevalence of neurological disorders in humans is rising year after year. This fact necessitates the development of new drugs for treating these pathologies... |
PMC3669588 | core_pubmed_pmc | Adverse drug reactions in the elderly | Adverse drug reactions in the elderly Abstract Abstract Medications probably are the single most important health care technology in preventing illness, disability, and death in the geriatric population. Age-related changes in drug disposition and pharmacodynamic responses have significant clinical implications; increa... |
PMC10467199 | core_pubmed_pmc | Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies | Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies Abstract Abstract Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and de... |
PMC9525219 | core_pubmed_pmc | The pharmacology, pharmacokinetics, and toxicity of spinosin: A mini review | The pharmacology, pharmacokinetics, and toxicity of spinosin: A mini review Abstract Spinosin, a natural flavone- C -glycoside that is mainly isolated from the seeds of Ziziphus jujuba Mill . var. spinosa . It exerts the effects to ameliorate the neurological disorders, such as hypnosis effects, improvement of cognitiv... |
PMC10530724 | core_pubmed_pmc | Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs | Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs Abstract The escalating prevalence of drug-resistant strains of Mycobacterium tuberculosis has posed a significant challenge to global efforts in combating tuberculosis. To address this issue, innovative therape... |
PMC6076123 | core_pubmed_pmc | Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes | Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes Abstract Abstract Background: Metformin is one of the most commonly used drugs for the treatment of type 2 diabetes mellitus (T2DM). Despite its widespread use, there are considerable inte... |
PMC12589665 | core_pubmed_pmc | Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys | Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys Abstract Interleukin-13 (IL-13) is a cytokine implicated in the pathophysiology of type 2 inflammatory diseases and is a clinically validated target in atopic dermatitis. APG777 is a humanized IgG1 mo... |
PMC8455402 | core_pubmed_pmc | Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia | Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia Abstract Dual orexin receptor antagonists (DORAs) represent a novel type of sleep medication that provide an alternative to the traditionally used positive allosteric gamma-aminobutyric acid (GABA)-A receptor m... |
PMC9214490 | core_pubmed_pmc | Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study | Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study Abstract Significance There is a great need for novel approaches to the treatment of ductal carcinoma in situ, which affects 69,000 women per year in the United St... |
PMC11671329 | core_pubmed_pmc | Optimizing β‐lactam‐containing antibiotic combination therapy for the treatment of Buruli ulcer | Optimizing β‐lactam‐containing antibiotic combination therapy for the treatment of Buruli ulcer Abstract Abstract Aims The current treatment for Buruli ulcer is based on empirical evidence of efficacy. However, there is an opportunity for shortening its duration and improving response rates. Evolving understanding of t... |
PMC4703733 | core_pubmed_pmc | A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia | A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia Abstract Abstract Background Vitamin E δ-tocotrienol (VEDT), a natural vitamin E from plants, has shown anti-neoplastic and chemoprevention activity in preclinical models of p... |
PMC8447726 | core_pubmed_pmc | Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules | Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules Abstract Human serum albumin (HSA) is the most prevalent protein in the blood plasma which binds an array of exogenous compounds. Drug binding to HSA is an importan... |
PMC11323397 | core_pubmed_pmc | In vivo fluorescence imaging of nanocarriers in near-infrared window II based on aggregation-caused quenching | In vivo fluorescence imaging of nanocarriers in near-infrared window II based on aggregation-caused quenching Abstract Accurate fluorescence imaging of nanocarriers in vivo remains a challenge owing to interference derived mainly from biological tissues and free probes. To address both issues, the current study explore... |
PMC12342004 | core_pubmed_pmc | Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants | Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants Abstract Abstract Losartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxy... |
PMC4346364 | core_pubmed_pmc | Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation | Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation Abstract Z-GP-Dox, the FAPα (fibroblast activation protein-α)-based doxorubicin prodrug, demonstrates excellent tumor targeting effects and a favorable toxicokinetic ... |
PMC6761782 | core_pubmed_pmc | Pharmacology related to paediatric anaesthesia | Pharmacology related to paediatric anaesthesia Abstract Abstract A child is not a mini adult. They differ from adults in terms of weight, shape, anatomical size and major body systems such as cardiovascular and respiratory as well as psychologically. Each organ system is immature in paediatric age group and their growt... |
PMC6990742 | core_pubmed_pmc | Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease | Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease Abstract Key Points Question Is the use of nilotinib hydrochloride, a drug approved for use in leukemia, safe and effective in patients with Parkinson disease? Findings In this randomized clinical trial of use of nilotinib hydrochl... |
PMC11069587 | core_pubmed_pmc | An Elastin-like Polypeptide-fusion peptide targeting capsid-tegument interface as an antiviral against cytomegalovirus infection | An Elastin-like Polypeptide-fusion peptide targeting capsid-tegument interface as an antiviral against cytomegalovirus infection Abstract Abstract The tegument protein pp150 of Human Cytomegalovirus (HCMV) is known to be essential for the final stages of virus maturation and mediates its functions by interacting with c... |
PMC12753540 | core_pubmed_pmc | Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study | Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study Abstract Background Ceralasertib is an oral, selective, and potent inhibitor of ATR serine/threonine kinase, a key protein involved in cell cycle checkpoint regulation and DNA damage... |
PMC8453848 | core_pubmed_pmc | Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies | Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies Abstract Abstract GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; there... |
PMC6017000 | core_pubmed_pmc | Distribution Assessments of Coumarins from Angelicae Pubescentis Radix in Rat Cerebrospinal Fluid and Brain by Liquid Chromatography Tandem Mass Spectrometry Analysis | Distribution Assessments of Coumarins from Angelicae Pubescentis Radix in Rat Cerebrospinal Fluid and Brain by Liquid Chromatography Tandem Mass Spectrometry Analysis Abstract Angelicae Pubescentis Radix (APR) is a widely-used traditional Chinese medicine. Pharmacological studies have begun to probe its biological acti... |
PMC4111403 | core_pubmed_pmc | Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies | Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies Abstract Microtubule (MT) stabilizing drugs hold promise as potential treatments for Alzheimer’s disease (AD) and related tauopathies. However, thus far epoth... |
PMC11464410 | core_pubmed_pmc | Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy | Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Abstract Abstract Background Tigecycline is considered one of the last resorts for treating infections caused by multidrug-resistant bacteria. Continuous renal replacement therapy (CRRT) is widely used... |
PMC10936634 | core_pubmed_pmc | Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies | Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies Abstract ABSTRACT Bispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer promising therapeutic options for various diseases by targeting multiple pathways. The favorable pharmacokinet... |
PMC12721511 | core_pubmed_pmc | Bioactive fungal metabolites as SIRT2 antagonists: A computational quest for cancer treatment | Bioactive fungal metabolites as SIRT2 antagonists: A computational quest for cancer treatment Abstract SIRT2, a member of the sirtuin protein family, plays a pivotal role in regulating tumor progression by modulating key metabolic pathways and signaling proteins. The regulatory role of this protein has been documented ... |
PMC6585626 | core_pubmed_pmc | Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule | Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule Abstract Abstract A new formulation of levothyroxine sodium has been developed in the form of an oral solution contained in unit‐dose ampules. A study has been conducted to compare the bioavailability of levothyrox... |
PMC7955741 | core_pubmed_pmc | Precisely Fabricated Sulpiride-Loaded Nanolipospheres with Ameliorated Oral Bioavailability and Antidepressant Activity | Precisely Fabricated Sulpiride-Loaded Nanolipospheres with Ameliorated Oral Bioavailability and Antidepressant Activity Abstract Abstract Background Sulpiride (SUL), is a selective antidopaminergic drug that had extensive biological activities. However, its sparingly aqueous solubility and limited gastrointestinal perm... |
PMC3082041 | core_pubmed_pmc | Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors | Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors Abstract Purpose A single-agent dose-escalating phase I and pharmacokinetic study on TSU-68, a novel multiple receptor tyrosine kinase... |
PMC12238943 | core_pubmed_pmc | First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors | First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors Abstract Abstract Background Immune checkpoint receptor lymphocyte-activation gene 3 (LAG-3) is an activation marker for CD4 + and CD8 + T cells. Prolonged LAG-3 expression do... |
PMC8003833 | core_pubmed_pmc | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients Abstract Simple Summary Vitamin C is an indispensable micronutrient in the human diet due to the multiple functions it carries out in the body. Reports of clinical studies have indicated that, when administered at high dosage by the in... |
PMC3364283 | core_pubmed_pmc | Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma | Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma Abstract Abstract Background Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated with poor perform... |
PMC8850389 | core_pubmed_pmc | A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study | A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study Abstract Abstract Background: Linezolid-induced thrombocytopenia (LIT) is the main factor limiting the clinical application of linezolid (LZD). The incidence and risk factors of LIT in neo... |
PMC8247037 | core_pubmed_pmc | Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study | Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study Abstract Summary Background Children aged ≥ 6 to < 12 years with severe atopic dermati... |
PMC4674149 | core_pubmed_pmc | Model-Based Tumor Growth Dynamics and Therapy Response in a Mouse Model of De Novo Carcinogenesis | Model-Based Tumor Growth Dynamics and Therapy Response in a Mouse Model of De Novo Carcinogenesis Abstract Abstract Tumorigenesis is a complex, multistep process that depends on numerous alterations within the cell and contribution from the surrounding stroma. The ability to model macroscopic tumor evolution with high ... |
PMC7192714 | core_pubmed_pmc | Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension | Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension Abstract Information regarding the pharmacokinetics of oral sildenafil in dogs with pulmonary hypertension is limited. In this study, we examined the pharmacokinetics of oral sildenafil in a canine ... |
PMC11768370 | core_pubmed_pmc | Etodolac Single Dose Metabolic Profile Elucidation: Pharmacokinetics and Adverse Events in Healthy Volunteers | Etodolac Single Dose Metabolic Profile Elucidation: Pharmacokinetics and Adverse Events in Healthy Volunteers Abstract Background/Objectives: This study investigates the metabolic profile of a single dose of etodolac in healthy volunteers, focusing on pharmacokinetics, clinical parameters, and metabolomic variations to... |
PMC11189489 | core_pubmed_pmc | A platform technology for ultra-long acting intratumoral therapy | A platform technology for ultra-long acting intratumoral therapy Abstract Intratumoral (IT) therapy is a powerful method of controlling tumor growth, but a major unsolved problem is the rapidity that injected drugs exit tumors, limiting on-target exposure and efficacy. We have developed a generic long acting IT deliver... |
PMC3764125 | core_pubmed_pmc | Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach | Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach Abstract Background Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as Multiple Sclerosis (MS). A clinical relapse in MS reflects an acute focal inflammatory event in the centr... |
PMC10266203 | core_pubmed_pmc | The dilemma of antibiotic susceptibility and clinical decision-making in a multi-drug-resistant Pseudomonas aeruginosa bloodstream infection | The dilemma of antibiotic susceptibility and clinical decision-making in a multi-drug-resistant Pseudomonas aeruginosa bloodstream infection Abstract Objective: How to choose the appropriate antibiotics and dosage has always been a difficult issue during the treatment of multi-drug-resistant bacterial infections. Our s... |
PMC3357340 | core_pubmed_pmc | Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine Malaria Model | Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine Malaria Model Abstract Iron chelators for the treatment of malaria have proven therapeutic activity in vitro and in vivo in both humans and mice, but their clinical use is limited by th... |
PMC12944243 | core_pubmed_pmc | Patient Median-Based Quality Control in Lamotrigine Therapeutic Drug Monitoring: A 15-Year Retrospective Study | Patient Median-Based Quality Control in Lamotrigine Therapeutic Drug Monitoring: A 15-Year Retrospective Study Abstract Abstract Background/Objectives: Lamotrigine is an anticonvulsant and mood stabilizer with wide interindividual pharmacokinetic variability, necessitating therapeutic drug monitoring (TDM). Patient-bas... |
PMC11596910 | core_pubmed_pmc | Sclareolide as Antifungal Strategy Against Cryptococcus neoformans : Unveiling Its Mechanisms of Action | Sclareolide as Antifungal Strategy Against Cryptococcus neoformans : Unveiling Its Mechanisms of Action Abstract Abstract Cryptococcal infection commonly begins as an opportunistic infection in humans, however, this can escalate to a systemic or life-threatening form in immunocompromised individuals. Here, we aim to id... |
PMC6767458 | core_pubmed_pmc | The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis | The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis Abstract Abstract Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double‐blind, placebo‐controlled study, we tested... |
PMC7496780 | core_pubmed_pmc | Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden | Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden Abstract Abstract Objectives Taking advantage of its food‐dependent bioavailability, the present study investigated the effect of a reduced dose taken with real‐life meals on the pharmacokine... |
PMC9092580 | core_pubmed_pmc | Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders | Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders Abstract The Organ-on-a-Chip (OoC) technology shows great potential to revolutionize the drugs development pipeline by mimicking the physiological environment and functions of human organs. T... |
PMC12350491 | core_pubmed_pmc | Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI | Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI Abstract Abstract Objectives This study aimed to assess whether pharmacokinetic parameters derived from DCE-MRI can stratify Programmed Death-Ligand 1 (PD-L1) expression in NSCLC. The secondary aim was to identify a suit... |
PMC4505824 | core_pubmed_pmc | Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making | Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making Abstract Abstract It is no coincidence that the reports of two meetings, one organized by the US Food and Drug Administration (FDA), in March 2014, and the other by the UK Medicines and Healthcare Products Regulatory (MH... |
PMC7546276 | core_pubmed_pmc | Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats | Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats Abstract The objective of this study was to develop a non-linear mixed-effects (NLME) model to describe the disposition kinetics of vitacoxib in cats following intravenous (I.V) and oral (P.O) (single and multiple... |
PMC8860177 | core_pubmed_pmc | Kratom Abuse Potential 2021: An Updated Eight Factor Analysis | Kratom Abuse Potential 2021: An Updated Eight Factor Analysis Abstract Drugs are regulated in the United States (US) by the Controlled Substances Act (CSA) if assessment of their abuse potential, including public health risks, show such control is warranted. An evaluation via the 8 factors of the CSA provides the compr... |
PMC9686876 | core_pubmed_pmc | Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma | Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma Abstract Abstract Simple Summary This study was designed to assess the effect of metronomic cyclophosphamide on carboplatin’s tolerability, efficacy, and pharmacokinetics in female dogs with mammary carci... |
PMC3534360 | core_pubmed_pmc | Pharmacokinetic-Pharmacodynamic Model of Newly Developed Dexibuprofen Sustained Release Formulations | Pharmacokinetic-Pharmacodynamic Model of Newly Developed Dexibuprofen Sustained Release Formulations Abstract Pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical pharmacology to optimize drug use by designing rational dosage forms and dosage regimes. Quantitative representation of t... |
PMC12089623 | core_pubmed_pmc | Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia | Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia Abstract Abstract Introduction TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) agent that combines risperidone and an innovative, copolymer-based drug deliv... |
PMC12653854 | core_pubmed_pmc | Physiologically Based Pharmacokinetic Modeling of Clobazam and Stiripentol Co-Therapy in Dravet Syndrome | Physiologically Based Pharmacokinetic Modeling of Clobazam and Stiripentol Co-Therapy in Dravet Syndrome Abstract Background : Dravet syndrome, a severe early-onset epileptic encephalopathy, is treated with multiple antiepileptic drugs such as clobazam (CLB) and stiripentol (STP), increasing the risk of drug–drug inter... |
PMC8857469 | core_pubmed_pmc | Application of exposure bracketing to streamline the development of contraceptive products ☆ | Application of exposure bracketing to streamline the development of contraceptive products ☆ Abstract Developing new long-acting products of well-characterized contraceptive drugs is one way to address some of the reasons for unmet need for modern methods of family planning among women in low- and middle-income countri... |
PMC9740824 | core_pubmed_pmc | Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome | Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome Abstract The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effective... |
PMC4546118 | core_pubmed_pmc | Enhanced oral bioavailability of vancomycin in rats treated with long-term parenteral nutrition | Enhanced oral bioavailability of vancomycin in rats treated with long-term parenteral nutrition Abstract Long-term parenteral nutrition (PN) can induce intestinal atrophy, leading to a loss of epithelial integrity in the small intestines. This change may alter the intestinal permeability of vancomycin (VCM), a non-abso... |
PMC4937634 | core_pubmed_pmc | Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy—a proof of concept analysis | Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy—a proof of concept analysis Abstract Abstract Objective Famotidine given at a dose of 80 mg/day is effective in preventing NSAID-induced gastropathy. The ai... |
PMC12729784 | core_pubmed_pmc | Linezolid Serum Concentration Variability Among Critically Ill Patients Based on Renal Function and Continuous Renal Replacement Therapy Administration | Linezolid Serum Concentration Variability Among Critically Ill Patients Based on Renal Function and Continuous Renal Replacement Therapy Administration Abstract Abstract Background: Linezolid standard dosing is typically applied in ICU without adjustments, even in renal impairment. This study examines serum concentrati... |
PMC11031409 | core_pubmed_pmc | Spatial Bayesian distributed lag non-linear models (SB-DLNM) for small-area exposure-lag-response epidemiological modelling | Spatial Bayesian distributed lag non-linear models (SB-DLNM) for small-area exposure-lag-response epidemiological modelling Abstract Abstract Background Distributed lag non-linear models (DLNMs) are the reference framework for modelling lagged non-linear associations. They are usually used in large-scale multi-location... |
PMC5571323 | core_pubmed_pmc | Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics | Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics Abstract ABSTRACT Cefiderocol (S-649266), a novel siderophore cephalosporin, shows potent activity against carbapenem-resistant Gram-negative baci... |
PMC11325084 | core_pubmed_pmc | Pharmacokinetics and tissue distribution of LN002, a new compound alternative oxidase inhibitor against Cryptosporidium in rats | Pharmacokinetics and tissue distribution of LN002, a new compound alternative oxidase inhibitor against Cryptosporidium in rats Abstract Abstract Cryptosporidiosis is considered a crucial zoonotic disease caused by widely distributing parasitic protozoa called Cryptosporidium spp. Nitazoxanide is the only FDA-approved ... |
PMC5429760 | core_pubmed_pmc | Development of Mixed metal Metal-organic polyhedra networks, colloids, and MOFs and their Pharmacokinetic applications | Development of Mixed metal Metal-organic polyhedra networks, colloids, and MOFs and their Pharmacokinetic applications Abstract Summary The coordination networking of discrete metal-organic polyhedra (MOPs) involving different ligands as well as metals is a challenging task due to the features of limited solubility and... |
PMC12588010 | core_pubmed_pmc | Validation method for determining the concentration of norfloxacin-tylosin combination in broiler chicken tissue using high-performance liquid chromatography | Validation method for determining the concentration of norfloxacin-tylosin combination in broiler chicken tissue using high-performance liquid chromatography Abstract Background: The combination of norfloxacin and tylosin is an alternative to prevent antibiotic residue and resistance. Measurement of the levels of the c... |
PMC10719894 | core_pubmed_pmc | Standards for clinical trials for treating TB | Standards for clinical trials for treating TB Abstract BACKGROUND: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice. METHODS: A global panel of experts participated in a Delphi process, using a 7-point Likert sca... |
PMC8569112 | core_pubmed_pmc | Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis | Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis Abstract Abstract Background: While tuberculosis (TB) is curable and preventable, the most effective first-line antibiotics cannot kill multi-drug resistant (MDR) Mycobacterium tuberculosis ( Mtb ). Therefore, effective drugs... |
PMC11708054 | core_pubmed_pmc | Variation in human gut microbiota impacts tamoxifen pharmacokinetics | Variation in human gut microbiota impacts tamoxifen pharmacokinetics Abstract ABSTRACT Tamoxifen is the most prescribed drug used to prevent breast cancer recurrence, but patients show variable responses to tamoxifen. Such differential inter-individual response has a significant socioeconomic impact as one in eight wom... |
PMC4590719 | core_pubmed_pmc | Comparative pharmacokinetics of tetramethylpyrazine phosphate in rat plasma and extracellular fluid of brain after intranasal, intragastric and intravenous administration | Comparative pharmacokinetics of tetramethylpyrazine phosphate in rat plasma and extracellular fluid of brain after intranasal, intragastric and intravenous administration Abstract The purpose of this study was to compare the pharmacokinetic profiles of tetramethylpyrazine phosphate (TMPP) in plasma and extracellular fl... |
PMC3942693 | core_pubmed_pmc | Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization | Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization Abstract Prodrugs are chemistry-enabled drug delivery modifications of active molecules designed to enhance their pharmacokinetic, pharmacodynamic and/or biopharmaceutical properties. Ideally, prodrugs are efficiently c... |
PMC4878067 | core_pubmed_pmc | Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin | Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin Abstract Abstract Quinolones are potent antimicrobial agents with a basic chemical structure of bicyclic ring. Fluorine atom at position C-6 and various substitutions ... |
PMC3163372 | core_pubmed_pmc | Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem Mass Spectrometry and its Application to a Pharmacokinetic Study | Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem Mass Spectrometry and its Application to a Pharmacokinetic Study Abstract Abstract In this study, authors developed a simple, sensitive and specific liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for quantification o... |
PMC12242633 | core_pubmed_pmc | PEGylating Ag 2 S Semiconductor Nanocrystals for Pharmacokinetics Tracking: Insights from NIR Luminescence Imaging | PEGylating Ag 2 S Semiconductor Nanocrystals for Pharmacokinetics Tracking: Insights from NIR Luminescence Imaging Abstract Abstract Nanotechnology has revolutionized biomedical applications through the development of nanomaterials with tailored properties, particularly in disease diagnosis and treatment. However, chal... |
PMC9404640 | core_pubmed_pmc | A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study | A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study Abstract Abstract Background Publications sugge... |
PMC7555137 | core_pubmed_pmc | Pharmacokinetics of Repeated Oral Dosing with Coenzyme Q10 in Cavalier King Charles Spaniels with Myxomatous Mitral Valve Disease | Pharmacokinetics of Repeated Oral Dosing with Coenzyme Q10 in Cavalier King Charles Spaniels with Myxomatous Mitral Valve Disease Abstract Abstract Coenzyme Q10 (Q10) is a mitochondrial cofactor and an antioxidant with the potential to combat oxidative stress in heart failure. This study aims to determine the pharmacok... |
PMC8981703 | core_pubmed_pmc | Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study | Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study Abstract Abstract Background Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated signi... |
PMC12146200 | core_pubmed_pmc | Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies | Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies Abstract Abstract This mini-review provides an update on the challenges and controversies surrounding levothyroxine therapy in thyroidectomized patients, following an extensive review on dosing strategies and available formulations... |
PMC12078878 | core_pubmed_pmc | Are we ignoring sex differences in haematological malignancies? A call for improved reporting | Are we ignoring sex differences in haematological malignancies? A call for improved reporting Abstract Summary There are clear sex‐based differences in the incidence, risk factors and mortality of most haematologic malignancies (HM). Despite known differences in physiology, haematopoiesis, molecular profiles, drug phar... |
PMC11128490 | core_pubmed_pmc | Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling | Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling Abstract Abstract Niclosamide, a potent anthelmintic agent, has emerged as a candidate against COVID‐19 in recent studies. Its formulation has been investigated extensively to address challenges related... |
PMC5538305 | core_pubmed_pmc | Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients | Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients Abstract Background: Invasive fungal infection (IFI) is one of the leading causes of early death after renal transplantation. Voriconazole (VRC) is the first-line drug of IFI. Because of the large inter- and in... |
PMC12953490 | core_pubmed_pmc | Pharmacogenomics and genetic ancestry: an opportunity to transform clinical practice in Colombia | Pharmacogenomics and genetic ancestry: an opportunity to transform clinical practice in Colombia Abstract Abstract Pharmacogenomics has emerged as a clinically actionable discipline capable of reducing inter-individual variability in drug response, adverse drug reactions, and therapeutic failure. However, its real-worl... |
PMC10675556 | core_pubmed_pmc | The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy | The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy Abstract Five-membered heterocycles are essential structural components in various antibacterial drugs; the physicochemical properties of a five-membered heterocycle can play a crucial role in determining the biolog... |
PMC12065538 | core_pubmed_pmc | A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies | A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies Abstract Abstract Background Venetoclax is a selective small-molecule BCL-2 inhibitor that has been approved for treating hematologic malignancies. Co-administration with CYP3A inhibitors, such as v... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.